What They Build
Mynvax develops thermostable vaccines and immunogens, including work on influenza and coronavirus vaccine candidates.
Why They Matter
Thermostability is not a minor convenience in countries where cold chains shape access. Mynvax matters because it works on vaccine design and delivery constraints together. The path from platform promise to approved product remains long, regulated, and expensive.
Founders
Raghavan Varadarajan, Girish Sahni
Recent Milestones
- Thermostable vaccine candidates disclosed
- COVID-era vaccine work reported
- Biotech funding and grants announced